Pharma & Tech 052720
Pharma Cash to Congress
By Elizabeth Lucas and KFF Health News Staff
A KFF Health News database tracks campaign donations from drugmakers over the past 10 years.
Analysis: Get Ready For The Vaccine — They’re Never Simple
By Arthur Allen
Trials are an immense undertaking involving tens of thousands of participants. They’re likely to start this summer — but don’t expect quick results. And what’s a successful result, anyway?
Drugmakers Tout COVID-19 Vaccines To Refurbish Their Public Image
By Jay Hancock
Vaccines and antivirals have long been an afterthought but Johnson & Johnson and other firms are widely publicizing how they might stop COVID 19.
Chasing The Elusive Dream Of A COVID Cure
By Liz Szabo
Thousands of researchers worldwide are looking for a treatment that will go beyond what remdesivir can do for COVID patients.
Trump Touted Abbott’s Quick COVID-19 Test. HHS Document Shows Only 5,500 Are On Way For Entire U.S.
By Rachana Pradhan
States urgently need millions of tests, and the game changer they’ve been waiting on falls well short of what is needed, according to government documents obtained by KHN.
Listen: A New Hope In The Battle Against COVID-19
KHN’s Julie Rovner joins a panel of journalists on “1A” to talk about promising results in a study of the drug remdesivir and other developments in the battle against the coronavirus.
Persiguiendo el esquivo sueño de una cura para COVID-19
By Liz Szabo
Hay más de 1,250 estudios de COVID-19 en marcha. Las farmacéuticas están invirtiendo miles de millones en el desarrollo de medicamentos y vacunas eficaces para poner fin a la pandemia.